Cargando…

Plasma and tumoral glypican‐3 levels are correlated in patients with hepatitis C virus‐related hepatocellular carcinoma

Glypican‐3 (GPC3) is a cancer antigen expressed in approximately 80% of hepatocellular carcinomas (HCC) and is secreted into the blood. To confirm the effectiveness of GPC3 as a biomarker in HCC, we analyzed the relationship between GPC3 expression levels in cancer cells and in blood in 56 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Yasuhiro, Mizuno, Shoichi, Fujinami, Norihiro, Suzuki, Toshihiro, Saito, Keigo, Konishi, Masaru, Takahashi, Shinichiro, Gotohda, Naoto, Tada, Toshifumi, Toyoda, Hidenori, Kumada, Takashi, Miura, Masahiro, Suto, Kouzou, Yamaji, Taiki, Matsuda, Takahisa, Endo, Itaru, Nakatsura, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004540/ https://www.ncbi.nlm.nih.gov/pubmed/31774932 http://dx.doi.org/10.1111/cas.14251

Ejemplares similares

Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery
por: Miura, Masahiro, et al.
Publicado: (2020)

Peptide vaccine as an adjuvant therapy for glypican‐3‐positive hepatocellular carcinoma induces peptide‐specific CTLs and improves long prognosis
por: Taniguchi, Masatake, et al.
Publicado: (2020)

Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
por: Ofuji, Kazuya, et al.
Publicado: (2016)

Next-Generation Cancer Immunotherapy Targeting Glypican-3
por: Shimizu, Yasuhiro, et al.
Publicado: (2019)

Cancer immunotherapy‐targeted glypican‐3 or neoantigens
por: Shimizu, Yasuhiro, et al.
Publicado: (2018)

Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
por: Tsuchiya, Nobuhiro, et al.
Publicado: (2017)

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case
por: Sawada, Yu, et al.
Publicado: (2013)

Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery
por: Akazawa, Yu, et al.
Publicado: (2019)

Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification
por: Takahashi, Daigoro, et al.
Publicado: (2018)

Component with abundant immune‐related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis
por: Yagi, Naoki, et al.
Publicado: (2022)

Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
por: Tada, Toshifumi, et al.
Publicado: (2017)

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
por: Sawada, Yu, et al.
Publicado: (2016)

Pancreas‐preserving resection of lower biliary tract adenocarcinoma: A coring‐out technique
por: Nishida, Yasunori, et al.
Publicado: (2017)

Peptide-Based Vaccines for Hepatocellular Carcinoma: A Review of Recent Advances
por: Charneau, Jimmy, et al.
Publicado: (2021)

Early postoperative decrease of skeletal muscle mass predicts recurrence and poor survival after surgical resection for perihilar cholangiocarcinoma
por: Yasuta, Sho, et al.
Publicado: (2022)

A glypican-3-derived peptide vaccine against hepatocellular carcinoma
por: Sawada, Yu, et al.
Publicado: (2012)

Differences in the impact of prognostic factors for hepatocellular carcinoma over time
por: Toyoda, Hidenori, et al.
Publicado: (2017)

Predictive Factors for Anastomotic Leakage after Simultaneous Resection of Synchronous Colorectal Liver Metastasis
por: Nakajima, Kentaro, et al.
Publicado: (2011)

Hepatocellular Carcinoma with Foamy Histiocyte-Like Appearance: A Deceptively Clear Cell Carcinoma Appearing Variant
por: Noro, Takuji, et al.
Publicado: (2010)

Evaluation of liver function using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging based on a three-dimensional volumetric analysis system
por: Kudo, Masashi, et al.
Publicado: (2018)

Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan
por: Toyoda, Hidenori, et al.
Publicado: (2011)

Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide
por: TADA, YOSHITAKA, et al.
Publicado: ( 201)

Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy
por: Toyoda, Hidenori, et al.
Publicado: (2014)

Liver functional assessment using time-associated change in the liver-to-spleen signal intensity ratio on enhanced magnetic resonance imaging: a retrospective study
por: Kudo, Masashi, et al.
Publicado: (2023)

Glypicans
por: Filmus, Jorge, et al.
Publicado: (2008)

Development of antigen‐prediction algorithm for personalized neoantigen vaccine using human leukocyte antigen transgenic mouse
por: Charneau, Jimmy, et al.
Publicado: (2022)

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: Two case reports
por: Suzuki, Shiro, et al.
Publicado: (2014)

A case of mucinous cystic neoplasm of the liver: a case report
por: Nakayama, Yusuke, et al.
Publicado: (2015)

BRAF V600E potentially determines “Oncological Resectability” for “Technically Resectable” colorectal liver metastases
por: Kobayashi, Shin, et al.
Publicado: (2021)

The albumin–bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC
por: Ito, Takanori, et al.
Publicado: (2020)

Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus
por: Tachi, Yoshihiko, et al.
Publicado: (2015)

Natural history of liver‐related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model
por: Tada, Toshifumi, et al.
Publicado: (2019)

Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus
por: Kumada, Takashi, et al.
Publicado: (2021)

Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy
por: Kudo, Masashi, et al.
Publicado: (2022)

Non–clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell‐derived anti–glypican‐3 chimeric antigen receptor‐expressing natural killer/innate lymphoid cells
por: Ueda, Tatsuki, et al.
Publicado: (2020)

High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma
por: Kumada, Takashi, et al.
Publicado: (2013)

Long- and short-term outcomes of ERCP for bile duct stones in patients over 80 years old compared to younger patients: a propensity score analysis
por: Kanamori, Akira, et al.
Publicado: (2016)

Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus
por: Kumada, Takashi, et al.
Publicado: (2021)

Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma
por: Suzuki, Shiro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r1af4r2smok491t7f5pf9jia1q